BERKELEY HEIGHTS, N.J., April 4, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that Spiro Rombotis, President and Chief Executive Officer, will participate in a lymphoma and leukemia panel discussion at the Leerink Swann Cancer Roundtable conference on Thursday, April 7, 2011 at 2:15 p.m. Eastern Time at the Roosevelt Hotel in New York.
